{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:28:48Z","timestamp":1746088128847,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Merck Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00520-018-4515-4","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T13:55:31Z","timestamp":1539957331000},"page":"2295-2300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-8789","authenticated-orcid":false,"given":"Joseph M.","family":"Brandwein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack T.","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Rostom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Lutynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rydlewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen W. L.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"issue":"suppl 5","key":"4515_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):119\u2013133","journal-title":"Ann Oncol"},{"key":"4515_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1200\/JCO.2005.04.022","volume":"23","author":"O Geling","year":"2005","unstructured":"Geling O, Eichler HG (2005) Should 5-HT3 receptor antagonists be administered beyond 24 hours following chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294","journal-title":"J Clin Oncol"},{"key":"4515_CR3","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478","journal-title":"J Clin Oncol"},{"key":"4515_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/bjc.1997.507","volume":"76","author":"M Boer-Dennert De","year":"1997","unstructured":"De Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side effects of chemotherapy: the influence of 5-HT antagonists. Br J Cancer 76:1055\u20131061","journal-title":"Br J Cancer"},{"key":"4515_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational randomized double-blind placebo controlled trial in patients receiving high-dose cisplatin\u2014the aprepitant protocol 052 study group. J Clin Oncol 21:1\u20138","journal-title":"J Clin Oncol"},{"key":"4515_CR6","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodriguez-Pereira J, Ma GJ et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97:3090\u20133098","journal-title":"Cancer"},{"key":"4515_CR7","first-page":"114","volume":"893a","author":"P Stiff","year":"2009","unstructured":"Stiff P, Fox-Geiman MP, Kiley K et al (2009) A prospective randomized phase III trial of oral ondansetron and dexamethasone and the NK-1 inhibitor aprepitant for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Blood 893a:114","journal-title":"Blood"},{"key":"4515_CR8","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K, Freiberger A, H\u00fcsing J, Gronkowski M, Thalheimer M, Pelzl LH, Mikus G, Burhenne J, Ho AD, Egerer G (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413\u20133420","journal-title":"J Clin Oncol"},{"key":"4515_CR9","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830","journal-title":"J Clin Oncol"},{"key":"4515_CR10","first-page":"114","volume":"326a","author":"S Petersdorf","year":"2009","unstructured":"Petersdorf S, Kopecky AK, Stuart RK et al (2009) Preliminary results of southwest oncology group S0106: an international intergroup phase III randomized trial comparing the addition of gemtuzumab to standard induction chemotherapy versus standard induction chemotherapy for previously untreated acute myeloid leukemia. Blood 326a:114","journal-title":"Blood"},{"key":"4515_CR11","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/cncr.21006","volume":"103","author":"V Gupta","year":"2005","unstructured":"Gupta V, Chun K, Qi-Long Y et al (2005) Disease biology rather than age is the most important determinant of survival of AML patients \u226560 years treated with uniform intensive therapy. Cancer 103:2082\u20132090","journal-title":"Cancer"},{"key":"4515_CR12","doi-asserted-by":"publisher","first-page":"497597","DOI":"10.1155\/2015\/497597","volume":"2015","author":"T Badar","year":"2015","unstructured":"Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G et al (2015) Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int 2015:497597. \n                    https:\/\/doi.org\/10.1155\/2015\/497597","journal-title":"Biomed Res Int"},{"key":"4515_CR13","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"C Albany","year":"2012","unstructured":"Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 30:3998\u20134003","journal-title":"J Clin Oncol"},{"key":"4515_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s12185-015-1735-y","volume":"101","author":"R Nasu","year":"2015","unstructured":"Nasu R, Nannya Y, Kurokawa M (2015) A randomized controlled study evaluating the efficacy of aprepitant for highly\/moderately emetogenic chemotherapies in hematological malignancies. Int J Hematol 101:376\u2013385","journal-title":"Int J Hematol"},{"issue":"1","key":"4515_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/jcp.1041480108","volume":"148","author":"GS Wang","year":"1991","unstructured":"Wang GS, Wang C, Minkin S, Minden MD, McCulloch EA (1991) Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside. J Cell Physiol 148(1):60\u201367","journal-title":"J Cell Physiol"},{"issue":"6","key":"4515_CR16","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3324\/haematol.2017.184267","volume":"103","author":"S Bertoli","year":"2018","unstructured":"Bertoli S, Picard M, B\u00e9rard E, Griessinger E, Larrue C, Mouchel P-L et al (2018) Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica 103(6):988\u2013998 (in press)","journal-title":"Haematologica"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4515-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4515-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4515-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T19:20:38Z","timestamp":1571426438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4515-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4515"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4515-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"4 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received prior ethics approval by the local institutional review board and was registered at Clinicaltrials.gov (NCT01334086).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}